pioglitazone has been researched along with Cardiomyopathies, Primary in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, P; Hu, S; Lu, Q; Ren, Z; Wang, X; Wu, Q; Zhu, X | 1 |
| Fukushima, S; Kuratani, T; Maeda, N; Matsuura, R; Miyagawa, S; Mori, D; Sawa, Y; Shimomura, I; Sougawa, N; Toda, K; Tomita, K; Ueno, T | 1 |
| Brosius, FC; Hodgin, JB; Kaplan, MJ; Kretzler, M; Park, JL; Pennathur, S; Randolph, A; Somers, EC; Thacker, SG; Wang, JH; Zhang, H; Zhao, W | 1 |
| Asker, ME; Elrashidy, RA; Mohamed, HE | 1 |
4 other study(ies) available for pioglitazone and Cardiomyopathies, Primary
| Article | Year |
|---|---|
PPAR-γ with its anti-fibrotic action could serve as an effective therapeutic target in T-2 toxin-induced cardiac fibrosis of rats.
Topics: Anilides; Animals; Cardiomyopathies; Cell Line; Collagen; Fibrosis; Male; Myocardium; Pioglitazone; PPAR gamma; Rats, Wistar; Signal Transduction; T-2 Toxin; Transforming Growth Factor beta1; Up-Regulation | 2021 |
Pioglitazone strengthen therapeutic effect of adipose-derived regenerative cells against ischemic cardiomyopathy through enhanced expression of adiponectin and modulation of macrophage phenotype.
Topics: Adiponectin; Adipose Tissue; Animals; Cadherins; Cardiomyopathies; Cell Transplantation; Cells, Cultured; Disease Models, Animal; Interleukin-10; Interleukin-6; Macrophages; Male; Myocardial Infarction; Myocardium; Paracrine Communication; Phenotype; Pioglitazone; PPAR gamma; Rats, Inbred Lew; Recovery of Function; Regeneration; Signal Transduction; Stroke Volume; Ventricular Function, Left | 2019 |
The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus.
Topics: Animals; Cardiomyopathies; Disease Models, Animal; Endothelium, Vascular; Female; Inflammation Mediators; Kidney; Lupus Erythematosus, Systemic; Mice; Mice, Inbred NZB; Pioglitazone; PPAR gamma; Risk Factors; Stem Cells; Thiazolidinediones | 2009 |
Beneficial effects of pioglitazone against cardiovascular injury are enhanced by combination with aliskiren in a rat model of diabetic nephropathy.
Topics: Amides; Animals; Antihypertensive Agents; Cardiomyopathies; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Fumarates; Gene Expression Regulation; Hypoglycemic Agents; Lipid Peroxidation; Male; Matrix Metalloproteinase 2; Myocardium; Nephrectomy; Oxidative Stress; Pioglitazone; Rats; Rats, Wistar; Streptozocin; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-2; Transforming Growth Factor beta1 | 2012 |